Cancer
Conditions
Keywords
proteome, biomarkers, radiotherapy, cancer
Brief summary
The purpose of this study is to determine whether specific assays of DNA damage repair proteins can be used in patients undergoing radiation therapy. The ultimate goal of this research is to develop clinically useful biomarkers from blood samples that could be used to customize radiation treatment for individuals, leading to reduced side effects and improved outcomes.
Interventions
None listed
Sponsors
Virginia Mason Hospital/Medical Center
Fred Hutchinson Cancer Center
Benaroya Research Institute
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients \> 18 years of age with primary lung, esophageal or rectal cancer receiving neo-adjuvant chemoradiotherapy before planned resection * patients with clinically localized prostate cancer receiving definitive radiation therapy with external beam treatment. brachytherapy as a boost and/or hormonal therapy are allowed. * patients with head and neck, lung, esophageal or cervical cancer who will receive definitive radiotherapy
Exclusion criteria
* prior history of chemotherapy given within 6 months before enrollment. * prior radiotherapy or radionuclide treatment and/or brachytherapy within 6 months prior to enrollment. * unwillingness to comply with tests, protocol, or informed consent. * concurrent enrollment on any protocol that would require non-compliance with treatment procedures. * chemotherapy required within 2 hours following first dose of XRT. * PET scan done within 48 hours of first blood draw. * nuclear medicine exposure within 4 days prior to first draw.
Countries
United States
Outcome results
None listed